Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Karam, Irene ^a,b   Nichol, Alan ^a,b   Woods, Ryan ^b   Tyldesley, Scott ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Brain irradiation; Brain metastasis; Breast cancer; Her2 positive; Re irradiation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CRANIOTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION; TREATMENT OUTCOME; BRAIN TUMOR; BREAST TUMOR; CANCER GRADING; CHEMORADIOTHERAPY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SKULL IRRADIATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMORADIOTHERAPY; CRANIAL IRRADIATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84455173756     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-181     Document Type: Article

References (20)

1. Barnholtz-Sloan J, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol 2004, 22:2865-2872. 10.1200/JCO.2004.12.149, 15254054.
2. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27:5278-5286. 10.1200/JCO.2008.19.8481, 19770385.
3. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005, 31:256-273. 10.1016/j.ctrv.2005.04.007, 15951117.
4. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 1998, 280:1485-1489. 10.1001/jama.280.17.1485, 9809728.
5. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847. 10.1200/JCO.2009.22.1507, 19884552.
6. Slamon D, Leyland-Jones B, Shak S, et al. Addition of herceptin™ (humazined anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial [Abstract]. Proc Am Soc Clin Oncol 1998, 17:98a.
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
8. Stemmler H, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008, 13:739-750. 10.1634/theoncologist.2008-0052, 18614587.
9. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clinical Cancer Res 2007, 13:1648-1655.
10. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA: The Journal of the American Medical Association 1998, 280:1485-1489.
11. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751. 10.1016/S0360-3016(96)00619-0, 9128946.
12. Sadikov E, Bezjak A, Yi QL, et al. Value of whole brain re-irradiation for brain metastases -- single centre experience. Clin Oncol 2007, 19:532-538.
13. Diener-West M, Dobbins TW, Phillips TL, Nelson DF. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 1989, 16:669-673. 10.1016/0360-3016(89)90483-5, 2646260.
14. Abdel-Wahab MM, Wolfson AH, Raub W, et al. The role of hyperfractionated re-irradiation in metastatic brain disease: a single institutional trial. Am J Clin Oncol 1997, 20:158-160. 10.1097/00000421-199704000-00011, 9124191.
15. Cooper JS, Steinfeld AD, Lerch IA. Cerebral metastases: value of reirradiation in selected patients. Radiol 1990, 174:883-885.
16. Hazuka MB, Kinzie JJ. Brain metastases: results and effects of re-irradiation. Int J Radiat Oncol Biol Phys 1988, 15:433-437. 10.1016/S0360-3016(98)90026-8, 2841266.
17. Kurup P, Reddy S, Hendrickson FR. Results of re-irradiation for cerebral metastases. Cancer 1980, 46:2587-2589. 10.1002/1097-0142(19801215)46:12<2587::AID-CNCR2820461209>3.0.CO;2-4, 7448697.
18. Wong WW, Schild SE, Sawyer TE, Shaw EG. Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys 1996, 34:585-590. 10.1016/0360-3016(95)02156-6, 8621282.
19. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672. 10.1016/S0140-6736(04)16250-8, 15158627.
20. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655-661. 10.1016/j.ijrobp.2009.08.025, 19942357.